Lilly and Merck pair ‘breakthrough’ therapies in latest cancer collaboration

Damian Garde Eli Lilly and Merck are expanding their oncology partnership to study a combination of the former's top cancer prospect with the latter's blockbuster immunotherapy. FierceBiotech ...

Merck may appeal to Supreme Court after again losing fight to protect Cubicin patents

Eric Palmer Merck & Co. is running low on options after a federal appeals court Thursday again declined to back four patents that would have held at bay for 5 more years generics ...

Tesaro gets a green light for rolapitant, triggering Merck showdown

John Carroll The FDA has given Tesaro a green light to start marketing rolapitant to help prevent some of the common side effects of chemotherapy. And now Tesaro will wage a David-vs.-Goliath ...

Merck cancer drugs and Sanofi, Amgen cardio meds have formularies on high alert

Eric Palmer U.S. drug payers have been able to beat back high prices for some COPD and diabetes drugs, much to the chagrin of GlaxoSmithKline and Sanofi. But several new categories ...

Are CV studies worth it for diabetes meds? After Merck and Sanofi’s recent successes, some say no

Carly Helfand Some industry watchers are wondering whether those large, expensive trials–which aren't long enough to establish long-term outcomes–were worth it. FiercePharma ...

Merck launches Sivextro in U.K.

Eric Palmer Merck is launching Sivextro, the newly approved antibiotic it picked up in its $ 9.5 billion buyout of Cubist, in the U.K. Pharmafile reports it is the first oral treatment ...

Jury sides with Merck and its execs in gender-bias case

Tracy Staton Merck & Co. won the day in a gender discrimination suit on Tuesday, as a federal jury found that former employee Kerri Colicchio failed to prove she was discriminated ...

Merck bets big on NGM with a $450M handshake

Damian Garde Taking a page from famed partners like Sanofi and Regeneron and Roche and Genentech, Merck has signed a sweeping R&D deal with biotech NGM Biopharmaceuticals, promising ...

Merck KGaA expands diabetes presence in Middle East with new education program

Emily Wasserman Setting up camp in the Middle East is the trend du jour in Big Pharma, and Merck KGaA is expanding its footprint there by launching its new diabetes education program ...

Merck wins FDA approval for Gardasil’s heir

Damian Garde Merck won the FDA's blessing for a next-generation HPV vaccine designed to usurp Gardasil, putting it in line for billions in revenue. FierceBiotech News

Merck partners with Bind on a pair of new cancer drug programs

John Carroll Four months after Bind Therapeutics lost marquee development partner Amgen, Merck has stepped up to take the Big Biotech's place in the lineup. The pharma giant, which ...

Zilmax is safe, Merck says. But will the meat industry buy it?

Carly Helfand When it comes to cattle feed additive Zilmax, pulled from the market last year on concerning side-effect reports, there's nothing to worry about, Merck says. After ...
© 2018 Global Regulatory Science. All rights reserved. Site Admin · Entries RSS · Comments RSS